You are here
CERAMIDE THERAPEUTICS, LLC
UEI: N/A
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Single-chain antibody countermeasures for the Radiation GI Syndrome
Amount: $401,021.00DESCRIPTION provided by applicant Genetic or pharmacologic inhibition of ceramide mediated cell death within the vascular endothelium of the gastrointestinal tract GI protects mice from death fro ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD
Amount: $508,711.00DESCRIPTION (provided by applicant): Acute graft-versus-host disease (GvHD) is a primary complication of allogeneic stem cell transplantation, associated with wasting, immunosuppression and specific ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Selection of an anti-ceramide mitigator of acute radiation toxicity of the GI tra
Amount: $598,954.00DESCRIPTION (provided by applicant): The Gastrointestinal (GI) Syndrome is a primary complication of cancer treatments, associated with delivery of therapeutic doses of chemotherapy and radiation, and ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health
